Roivant Sciences Ltd

Stock Chart, Company Information, and Scan Results

$11.49(as of Jul 25, 12:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Roivant Sciences Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$11.49
Ticker SymbolROIV
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees750
CountyUSA
Market Cap$7,743.0M
EBIDTA-1,072.6M
10-Day Moving Average11.47
P/E Ratio-46.80
20-Day Moving Average11.31
Forward P/E Ratio0.00
50-Day Moving Average11.19
Earnings per Share-0.75
200-Day Moving Average11.18
Profit Margin-2,727.54%
RSI51.39
Shares Outstanding679.8M
ATR0.30
52-Week High13.06
Volume5,224,420
52-Week Low8.73
Most Recent Support Level11.38
Book Value5,187.2M
Most Recent Resistance Level11.64
P/B Ratio1.55
Upper Keltner11.99
P/S Ratio105.64
Lower Keltner10.64
Debt-to-Equity Ratio11.99
Next Earnings Date08/06/2025
Cash Surplus2,566.0M
Next Ex-Dividend DateUnknown

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd In Our Stock Scanner

As of Jul 25, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.